HIGHLIGHTS
- who: Pardeep S. Jhund from the School University of Wisconsin, Madison, WI, USA have published the article: Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER, in the Journal: (JOURNAL) of 26/07/2022
- what: There was a significant benefit of dapagliflozin on death from CV causes in DAPA-HF (HR 0.82 (95% CI 0.69-0.98)) but the present analysis provides a more reliable and precise estimate of the effect of treatment (HR 0.86 (95% CI 0 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.